Telmisartan and Lactulose drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Telmisartan and Lactulose. Common interactions include haemoglobin decreased among females and fall among males.

The phase IV clinical study analyzes what interactions people who take Telmisartan and Lactulose have. It is created by eHealthMe based on reports of 27 people who take Telmisartan and Lactulose from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 24, 2023

27 people who take Telmisartan and Lactulose together, and have interactions are studied.

What is Telmisartan?

Telmisartan has active ingredients of telmisartan. It is often used in high blood pressure. eHealthMe is studying from 4,365 Telmisartan users for its effectiveness, alternative drugs and more.

What is Lactulose?

Lactulose has active ingredients of lactulose. It is often used in constipation. eHealthMe is studying from 40,917 Lactulose users for its effectiveness, alternative drugs and more.

Number of Telmisartan and Lactulose reports submitted per year:

Common Telmisartan and Lactulose drug interactions by gender *:

female:

Haemoglobin decreased
Pyrexia
Arthralgia
Hypokalaemia
Acute myocardial infarction
Anaphylactic shock
Arthropathy
Chills
Diarrhoea
Dyspepsia

male:

Fall
Diarrhoea
Hypoglycaemia
Myocarditis
Pruritus
Suicide attempt
Alcoholism
Amylase increased
Arthralgia
Asthenia

Common Telmisartan and Lactulose drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Patella fracture

50-59:

n/a

60+:

Fall
Diarrhoea
Decreased appetite
Disease progression
Hyperkalaemia
Hypoglycaemia
Hypokalaemia
Myocarditis
Neutropenia
Pruritus

Common conditions people have *:

Pain: 8 people, 29.63%
Chest Pain: 6 people, 22.22%
Osteoporosis (bones weak and more likely to break): 6 people, 22.22%
Urinary Tract Infection: 5 people, 18.52%
Thyroid Diseases: 5 people, 18.52%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 5 people, 18.52%
Asthma: 5 people, 18.52%
Bladder Disorder: 5 people, 18.52%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 5 people, 18.52%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 5 people, 18.52%

* Approximation only. Some reports may have incomplete information.

Do you take Telmisartan and Lactulose?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Kato Y, Mukai Y, Rane A, Inotsume N, Toda T, "The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study", Biological and Pharmaceutical Bulletin, 2017 Sep .
Kim HK, Youm JB, Lee SR, Lim SE, Lee SY, Ko TH, Nilius B, Noh JH, Ko KS, Rhee BD, Kim N, "The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action", Pflügers Archiv-European Journal of Physiology, 2012 Dec .